Transitional cell carcinoma

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

This phase 2 trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery to people with muscle-invasive bladder cancer or upper tract urothelial carcinoma. The goal is to see if the drugs can shrink or eliminate the cancer enough that some b…

This study tests whether adding chemotherapy drugs (gemcitabine and mitomycin C) directly into the bladder alongside an immune-boosting drug (toripalimab) works better than toripalimab alone for people with a high-risk bladder cancer that did not respond to standard BCG therapy. …

This early-stage trial tests an experimental drug called STRO-006 in adults with advanced solid tumors, including head and neck, lung, esophageal, gastric, colorectal, endometrial, bladder, and breast cancers that have not responded to standard treatments. The study has three par…

This phase II trial compares a new targeted drug, sacituzumab tirumotecan (Sac-TMT), to other antibody-drug conjugates (ADCs) in people with advanced urothelial carcinoma (bladder cancer) that has worsened after prior treatment. The main goal is to see if Sac-TMT causes less seve…

This study tests a new drug called AK146D1, given alone or with another drug (AK112), in people with advanced urothelial carcinoma (a type of bladder cancer). The goal is to see if the treatment is safe and can shrink tumors. About 132 adults aged 18-75 with measurable tumors and…

This early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This early-stage trial tests a procedure called calcium electroporation for bladder tumors. Doctors inject calcium into the tumor and then apply short electric pulses to destroy cancer cells. The study will include 20 patients who cannot have standard surgery or other treatments.…

This phase 3 study tests a new drug called SYS6002 against standard chemotherapy in 406 people with advanced bladder cancer (urothelial carcinoma) that has worsened after platinum chemo and immunotherapy. The main goal is to see if SYS6002 helps people live longer. The study is n…

This study tests whether the drug avelumab can help keep metastatic urothelial carcinoma (a type of bladder cancer) from growing after patients have already received two lines of chemotherapy. About 144 adults whose cancer has not worsened after second-line chemo will receive ave…

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This study looks at whether a supportive product called Neuridase can help reduce nerve damage (peripheral neuropathy) caused by a combination of two cancer drugs (enfortumab vedotin and pembrolizumab) in people with advanced bladder cancer. About 40 participants will receive sta…

Researchers at M.D. Anderson Cancer Center are building a large collection of biological samples and clinical data from people with urothelial carcinoma, a common type of bladder cancer, and related urinary tract cancers. The study will enroll up to 50,000 adults with known or su…

This registry study follows bladder cancer patients who, after receiving systemic therapy, choose not to undergo bladder removal (cystectomy) or radiotherapy. The goal is to collect data on their outcomes, such as metastasis-free survival, to better understand which patients migh…

This study examines stored tumor samples from 100 bladder cancer patients who had their bladder removed. Researchers will measure the amount of supportive tissue, immune cells, and immune clusters near the tumor. The goal is to see if these features are linked to how long patient…